Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 141.30 4.40
Tata Mot 428.65 4.24
Bhel 181.05 3.10
Tata Stl 418.80 1.22
Ntpc Ltd 123.05 0.37
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Ipca Laboratories Limited
Ipca Laboratories Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:524494NSE:IPCALABBloomberg:IPCA@INReuters:IPCA.BO
Market Lot: 1Face Value: 2ISIN Demat: INE571A01020
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
03-MAR-14 Religare Institutional Research has reiterated `Buy` on Ipca Laboratories with revised target price of Rs 1,030 from Rs 880 in its report. 18-NOV-13 IPCA Laboratories, a Mumbai-based drugmaker, announced that the company has entered into an agreement with Avik Pharmaceutical (Avik) to acquire 50% of its paid-up equity share capital. 24-OCT-13 IPCA Laboratories, a Mumbai-based drugmaker, said on Thursday that the board of directors h...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
IPCA Lab surges as Morgan Stanley upgrades stock rating  -IRIS 21-Mar-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2013(9)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 24419.5027388.2022992.40
Other Income152.00186.60129.20
Total Income24571.5027574.8023121.60
Cost of goods sold18623.2021571.3018158.90
OPBDIT5948.306003.504962.70
PAT3403.403313.902801.70
Gross Block---
Equity capital252.40252.40252.30
EPS (Rs.)-26.2722.23
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-12.19 - 21.5810.36 - 15.83
Debt / Equity (x)---
Operating margin (% of OI)24.221.821.5
Net margin (% of OI)13.912.012.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
48, Kandivli Industrial Estate
Kandivli (West)
Mumbai
Maharashtra-400 067
PHONE
(022) 6647 4444
FAX
(022) 2868 6613
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer